Advances in Animal-Free Manufacturing of Biopharmaceuticals - New recombinant raw ingredients developed for use in large-scale mammalian cell culture are becoming readily available. - BioPharm

ADVERTISEMENT

Advances in Animal-Free Manufacturing of Biopharmaceuticals
New recombinant raw ingredients developed for use in large-scale mammalian cell culture are becoming readily available.


BioPharm International


Recombinant Human Albumin

Albumin is a 66-kDa plasma protein with a variety of physiological and stabilizing functions in vivo.13,14 In cell culture, albumin (usually in the form of BSA or HSA) is known to serve several important functions, including acting as a carrier protein and protecting cells from mechanical stress, and it is also thought to be a major serum survival factor, functioning as an inhibitor of apoptosis.15

Several recombinant human albumin (rHA) products are now commercially available and are offered as alternatives to HSA for a range of biopharmaceutical applications. rHA expressed from S. cerevisiae has been shown to exhibit similar safety, tolerability, and pharmacokinetic/pharmacodynamic profiles to native human albumin,10 and it has shown equivalent capacity to protect immunological, biological, and biochemical cell function.15

rHA from other yeast hosts, such as Aspergillus oryzae (for example, rProbuminAF), is being developed specifically for industrial cell culture use. Used as an ingredient in mammalian cell culture, such recombinant albumins can deliver quality, regulatory benefits, and performance benefits for both research and commercial-scale applications.

ANIMAL-FREE RECOMBINANT SUPPLEMENTS—A STEP IN THE RIGHT DIRECTION

New animal-free cell culture ingredients derived from microbial expression systems (such as those described above) offer a valuable solution to the quality and performance limitations of supplement regimes currently used with serum-free and protein-free media formulations for industrial-scale mammalian cell culture. Such ingredients, designed and manufactured exclusively to support biopharmaceutical manufacturing, bypass many regulatory hurdles and offer a secure, consistent supply for commercial-scale production.

ANIMAL-FREE TECHNOLOGY: THE MICROBIAL OPTION

Mammalian expression systems historically have been characterized as slow and expensive vehicles for the large-scale manufacturing of therapeutic proteins. They are, however, essential for the production of therapeutics that require complex post-translational modifications (PTMs), particularly glycosylation. O-linked and N-linked glycosylation patterns can influence protein stability, ligand binding, immunogenicity, and serum half-life, and they are significant in the context of efficacy of a wide range of biopharmaceuticals.1

On the other hand, microbial systems as models for the animal-free production of recombinant proteins on an industrial scale have much to offer the biopharmaceutical industry.

Unlike mammalian-based technology, microbial systems are typically grown in simple, chemically defined media. And, in the case of the proprietary E. coli and S. cerevisiae systems (which enabled the development of the recombinant ingredients described above) the entire production process is free from the use of animal- or human-derived materials.

With faster growth rates, high yields, and well understood genetics, microbial systems remain the obvious choice for expression of non-glycosylated peptides and proteins. Of the 31 therapeutic proteins approved since 2003, nine are produced in E. coli.15 However, in spite of this prokaryote lacking the ability to perform eukaryote -specific PTMs, it is widely used for the production of insulin, growth hormones, and growth factors. Yeast-based systems confer the advantages of high expression levels, easy molecular manipulation, and low costs of goods; in addition, as eukaryotes, yeast can perform PTMs, such as proteolytic processing, folding, disulphide bond formation, and glycosylation.

Since the 1980s, yeasts have been used for the large-scale production of recombinant proteins of human, animal, and plant origin. The brewer's yeast S. cerevisiae is an extremely well characterized eukaryotic system with "generally regarded as safe" (GRAS) status, and it was widely used for early protein production, including the first commercialized recombinant vaccine.16


blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

First Biosimilar Application Kicks Off Legal Battle
October 31, 2014
FDA Approves Pfizer's Trumenba for the Prevention of Meningitis B
October 30, 2014
EMA: Extrapolation Across Indications for Biosimilars a Possibility
October 30, 2014
Bristol-Myers Squibb Announces Agreement to Acquire HER2-Targeted Cancer Treatment
October 29, 2014
Amgen, Sanofi, and Ono Pharmaceuticals Partner with Universities on Transmembrane Protein Research
October 28, 2014
Author Guidelines
Source: BioPharm International,
Click here